Analysts predict that Recro Pharma Inc (NASDAQ:REPH) will post sales of $13.32 million for the current quarter, according to Zacks. Two analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from $13.30 million to $13.35 million. Recro Pharma reported sales of $17.36 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 23.3%. The company is expected to announce its next earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $13.32 million for the current year, with estimates ranging from $62.50 million to $66.14 million. For the next fiscal year, analysts anticipate that the company will report sales of $66.11 million per share, with estimates ranging from $63.60 million to $71.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative return on equity of 60.01% and a negative net margin of 51.88%.
In related news, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $9.56, for a total value of $126,086.84. Following the transaction, the insider now owns 2,243,064 shares of the company’s stock, valued at approximately $21,443,691.84. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 172,208 shares of the firm’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $9.45, for a total transaction of $1,627,365.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 860,414 shares of company stock valued at $8,289,916. 21.60% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in REPH. Teachers Advisors LLC bought a new position in Recro Pharma in the 2nd quarter valued at about $162,000. California State Teachers Retirement System bought a new position in Recro Pharma in the 2nd quarter valued at about $169,000. JPMorgan Chase & Co. lifted its position in Recro Pharma by 183.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 14,098 shares in the last quarter. Strs Ohio lifted its position in Recro Pharma by 455.0% in the 4th quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $205,000 after acquiring an additional 18,200 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new position in Recro Pharma in the 2nd quarter valued at about $215,000. 61.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of Recro Pharma (REPH) opened at $8.30 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma has a 1-year low of $5.81 and a 1-year high of $10.59. The firm has a market capitalization of $166.22, a PE ratio of -3.79 and a beta of -0.60.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.